trmt2b Antibody

What is TRMT2B and what is its biological function in cellular RNA methylation?

TRMT2B is a nuclear-encoded enzyme responsible for catalyzing 5-methyluridine (m5U) modifications in both mitochondrial tRNA and rRNA molecules. Specifically, TRMT2B:

• Introduces m5U54 in human mitochondrial tRNAs, including mt-tRNA Pro, mt-tRNA Asn, and mt-tRNA Gln

• Catalyzes m5U429 methylation in 12S mitochondrial rRNA

• Functions specifically in mitochondria, unlike its paralog TRMT2A which acts on cytosolic tRNAs

TRMT2B belongs to the family of tRNA methyltransferases that contribute to the epitranscriptome - the collection of post-transcriptional modifications in RNA molecules. While TRMT2B knockout studies show no obvious phenotype regarding RNA stability or mitochondrial translation, more detailed analysis reveals that TRMT2B inactivation leads to reduced activity of electron transport chain complexes I, III, and IV, which contain mitochondrially-encoded subunits .

The methyltransferase activity of TRMT2B depends on a conserved SAM binding site and catalytic residues, although interestingly, this enzyme appears to be catalytically inactive in bovine species due to evolutionary substitution of a critical cysteine residue .

How do TRMT2B antibodies differ from antibodies against other RNA methyltransferases?

TRMT2B antibodies specifically target unique epitopes of this mitochondrial methyltransferase that distinguish it from other RNA-modifying enzymes:

When designing experiments, researchers should be aware that TRMT2B shares sequence homology with other methyltransferases, particularly in the conserved SAM-binding domain. Therefore, validating antibody specificity against recombinant proteins or knockout cell lines is essential to ensure specificity for TRMT2B over its paralogs .

What are the optimal experimental conditions for TRMT2B antibody applications?

Different applications require specific optimization of TRMT2B antibody conditions:

Western Blot (WB)

• Recommended dilution: 1:500-1:1000

• Expected molecular weight: 50-56 kDa

• Positive control tissues/cells: HepG2 cells

• Buffer composition: PBS with 0.02% sodium azide and 50% glycerol (pH 7.3)

• Blocking solution: 5% non-fat milk in TBST

Immunohistochemistry (IHC)

• Recommended dilution: 1:20-1:200

• Antigen retrieval: TE buffer pH 9.0 (alternative: citrate buffer pH 6.0)

• Positive control tissues: Human liver cancer tissue, human colon tissue

• Detection system: HRP-DAB or fluorescent secondary antibody

ELISA

• Recommended dilution: 1:500-3000

• Coating buffer: Carbonate-bicarbonate buffer (pH 9.6)

• Blocking solution: 1-5% BSA in PBS

• Detection: HRP-conjugated secondary antibody and appropriate substrate

For optimal results, researchers should perform preliminary titration experiments to determine the ideal antibody concentration for their specific sample type and application .

What validation approaches ensure specific detection of TRMT2B?

Robust validation of TRMT2B antibodies should include multiple approaches to confirm specificity:

• Genetic validation:

  • Testing in TRMT2B knockout cell lines (e.g., HAP1 TRMT2B-KO cells as described in the literature)

  • siRNA-mediated TRMT2B knockdown (40-50% reduction has been achieved in studies)

  • Comparison with wild-type controls expressing normal levels of TRMT2B

• Biochemical validation:

  • Pre-adsorption with immunizing peptide/recombinant protein

  • Detection of appropriately sized band (50-56 kDa) by Western blot

  • Testing multiple antibodies targeting different epitopes

• Functional validation:

  • Colocalization studies with known mitochondrial markers (e.g., TOM20)

  • Correlation with m5U methylation status in mitochondrial RNAs using methods like primer extension following hydrazine/aniline treatment

  • Correlation with mitochondrial electron transport chain activity

Validation should include appropriate controls such as isotype control antibodies and cellular fractionation to confirm mitochondrial localization.

How can TRMT2B antibodies be used to investigate mitochondrial RNA methylation patterns?

TRMT2B antibodies can be employed in several experimental approaches to study mitochondrial RNA methylation:

• Immunofluorescence microscopy:

  • Visualize TRMT2B localization in mitochondria using confocal microscopy

  • Co-staining with mitochondrial markers like TOM20 confirms localization

  • Track changes in TRMT2B distribution under different cellular conditions

• Immunoprecipitation-based approaches:

  • RNA immunoprecipitation (RIP) to identify TRMT2B-associated RNAs

  • UV cross-linking immunoprecipitation (CLIP) to map precise TRMT2B binding sites

  • Methylation-iCLIP using catalytically inactive TRMT2B mutants (similar to approaches used for TRMT2A)

• Biochemical analysis coupled with antibody detection:

  • Western blot analysis of TRMT2B expression in mitochondrial fractions

  • Correlation of TRMT2B levels with m5U modification levels in mitochondrial RNAs

  • Comparison between different tissues with varying mitochondrial content

• Functional studies:

  • Analysis of respiratory chain complex activities in relation to TRMT2B levels

  • Measurement of mitochondrial protein synthesis efficiency using pulse-labeling techniques

  • Assessment of mitoribosome assembly in the presence/absence of TRMT2B

These approaches allow researchers to connect TRMT2B protein levels with specific RNA methylation patterns and functional outcomes in mitochondria.

What factors can affect TRMT2B antibody performance in experimental settings?

Several factors can influence the reliability and reproducibility of experiments using TRMT2B antibodies:

• Sample preparation variables:

  • Fixation method and duration for IHC applications

  • Lysis buffer composition for protein extraction (mitochondrial proteins require efficient extraction methods)

  • Storage conditions of samples and antibodies (freeze-thaw cycles can reduce antibody activity)

• Technical considerations:

  • Antibody lot-to-lot variability (validation with each new lot is recommended)

  • Secondary antibody selection and optimization

  • Detection method sensitivity (ECL, fluorescence, etc.)

• Biological variables:

  • Expression levels of TRMT2B vary between cell types and tissues

  • TRMT2B localization may change under specific cellular conditions

  • Post-translational modifications of TRMT2B may affect antibody binding

• Experimental design issues:

  • Lack of appropriate positive and negative controls

  • Insufficient blocking leading to high background

  • Inappropriate antibody dilution or incubation conditions

To minimize these issues, researchers should validate TRMT2B antibodies in their specific experimental system, include appropriate controls, and optimize protocols for their particular application and sample type.

How can TRMT2B antibodies be used in studies of mitoribosome biogenesis and function?

TRMT2B antibodies provide valuable tools for investigating mitoribosome assembly and function:

• Monitoring TRMT2B's role in mitoribosome assembly:

  • TRMT2B knockout systems have been used to study mitoribosomal small subunit (SSU) biogenesis

  • Depletion of TRMT2B stalls assembly intermediates, allowing for isolation and characterization of pre-SSU complexes

  • Western blot analysis with TRMT2B antibodies can confirm knockout/knockdown efficiency

• Analysis of TRMT2B-dependent rRNA modifications:

  • TRMT2B catalyzes m5U429 in 12S rRNA, located in helix 27 near the codon-anticodon interaction site

  • Immunoprecipitation of mitoribosomal complexes followed by RNA analysis can reveal TRMT2B-dependent modification patterns

  • Correlation between TRMT2B levels and modification status of specific rRNA positions

• Investigation of mitoribosomal protein interactions:

  • Co-immunoprecipitation using TRMT2B antibodies can identify protein interaction partners

  • Western blot analysis of mitoribosomal proteins in TRMT2B-depleted cells

  • Analysis of mitoribosome assembly intermediates that accumulate in the absence of TRMT2B

• Functional consequences of TRMT2B depletion:

  • Assessment of mitochondrial translation efficiency

  • Analysis of respiratory chain complex activities, which are reduced in TRMT2B knockout cells

  • Evaluation of mitoribosome integrity and stability

These approaches have revealed that TRMT2B depletion can be used to accumulate mitoribosomal assembly intermediates, making it a valuable tool for studying the sequential assembly of the mitochondrial ribosome .

What are the methodological approaches for detecting TRMT2B-catalyzed m5U modifications in RNA?

Several specialized techniques can be used in conjunction with TRMT2B antibodies to study m5U modifications:

• Hydrazine/aniline-based primer extension:

  • m5U modifications confer resistance to depyrimidination by hydrazine

  • Subsequent aniline treatment causes strand breakage at abasic sites

  • Primer extension assays show increased stalling at unmodified U positions in TRMT2B knockout/knockdown cells

  • This technique has been used to demonstrate TRMT2B-dependent m5U54 modification in mt-tRNAs and m5U429 in 12S rRNA

• Mass spectrometry-based approaches:

  • Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) can quantify m5U levels in RNA samples

  • TRMT2B knockdown results in approximately 37.7% reduction in m5U modifications per tRNA molecule

  • This method allows precise quantification of modification levels and can detect multiple modification types simultaneously

• Next-generation sequencing approaches:

  • Specialized sequencing methods like FICC-Seq (5-fluorouridine-induced cytidine conversion sequencing) can map m5U modifications transcriptome-wide

  • These approaches can be combined with TRMT2B antibody-based enrichment of specific RNA populations

• Functional correlation studies:

  • Analysis of tRNA charging status using acidic-PAGE to distinguish charged from uncharged tRNAs

  • Assessment of RNA stability following TRMT2B depletion

  • Evaluation of mitochondrial translation efficiency and accuracy

These methodological approaches provide complementary information about the presence, abundance, and functional consequences of TRMT2B-catalyzed m5U modifications.

How do experimental approaches differ when studying TRMT2B versus its paralog TRMT2A?

When designing experiments to specifically study TRMT2B as distinct from TRMT2A, researchers should consider several key differences:

Specific experimental considerations:

• Differential knockdown/knockout validation:

  • RT-qPCR with paralog-specific primers to confirm selective TRMT2B targeting

  • Western blot with paralog-specific antibodies to confirm protein depletion

  • Rescue experiments with paralog-specific expression constructs

• Substrate specificity analysis:

  • TRMT2B acts on mitochondrial tRNAs (mt-tRNA Pro, mt-tRNA Asn, mt-tRNA Gln)

  • TRMT2A targets cytosolic tRNAs, leading to different downstream effects

  • Analysis of m5U modifications in respective RNA populations

• Functional consequence analysis:

  • TRMT2B knockout affects respiratory chain complexes

  • TRMT2A knockdown triggers Angiogenin-dependent tRNA cleavage and 5'tiRNA generation

Understanding these differences is essential for proper experimental design and interpretation of results when studying these paralogous enzymes.

What are the technical challenges in detecting TRMT2B in tissue samples?

Researchers face several technical challenges when detecting TRMT2B in tissue samples:

• Fixation and antigen retrieval considerations:

  • Mitochondrial proteins often require specific fixation protocols to maintain antigenicity

  • Optimal antigen retrieval for TRMT2B antibodies involves TE buffer pH 9.0 or citrate buffer pH 6.0

  • Overfixation can mask epitopes, while underfixation may compromise tissue morphology

• Expression level variability:

  • TRMT2B expression varies across tissues based on mitochondrial content and activity

  • Expression analysis by RT-qPCR reveals differential expression across cell lines (e.g., higher in NS0 compared to NIH 3T3, Hepa1-6, and Aml12)

  • Sensitivity of detection methods must be optimized for tissues with lower expression

• Specificity considerations:

  • Cross-reactivity with TRMT2A must be ruled out

  • Non-specific binding in mitochondria-rich tissues may occur

  • Validation using TRMT2B knockout tissues as negative controls is ideal

• Antibody penetration issues:

  • Mitochondrial proteins may require enhanced permeabilization protocols

  • Balance between permeabilization and preservation of tissue architecture

  • Section thickness affects antibody penetration (optimal: 5-7 μm for IHC)

• Signal amplification requirements:

  • Endogenous TRMT2B may be present at relatively low levels

  • Signal amplification systems (e.g., tyramide signal amplification) may be necessary

  • Balance between sensitivity and background signal

Recommended approach: Optimize fixation and antigen retrieval protocols specifically for TRMT2B detection, validate antibody specificity using knockout controls, and employ appropriate signal amplification methods for low-abundance detection.

How can TRMT2B antibodies be utilized in studies of mitochondrial dysfunction and disease?

TRMT2B antibodies serve as valuable tools for investigating mitochondrial dysfunction in various pathological conditions:

• Analysis of TRMT2B expression in mitochondrial diseases:

  • Western blot quantification of TRMT2B levels in patient samples versus controls

  • IHC analysis of tissue samples to assess TRMT2B expression patterns

  • Correlation of TRMT2B levels with disease severity or progression

• Investigation of RNA modification defects:

  • Combined use of TRMT2B antibodies and m5U detection techniques

  • Assessment of m5U modifications in mitochondrial RNA from patient samples

  • Correlation between TRMT2B protein levels and modification status

• Functional studies in disease models:

  • Analysis of respiratory chain complex activities in relation to TRMT2B levels

  • Investigation of mitochondrial translation efficiency in disease states

  • Assessment of mitoribosome assembly and function

• Therapeutic intervention monitoring:

  • Tracking changes in TRMT2B expression following treatment

  • Correlation of TRMT2B restoration with functional improvement

  • Potential use as a biomarker for mitochondrial function recovery

• Cell-type specific analysis in complex tissues:

  • Multiplex immunofluorescence to examine TRMT2B in specific cell populations

  • Single-cell analysis of TRMT2B expression in heterogeneous tissue samples

  • Spatial relationship between TRMT2B expression and tissue pathology

While TRMT2B knockout shows no obvious phenotype in standard conditions , its role in respiratory chain complex activity suggests potential involvement in mitochondrial dysfunction under specific stress conditions or pathological states .

What methodological considerations are important when analyzing TRMT2B in different species?

When studying TRMT2B across different species, researchers should consider several important factors:

• Evolutionary conservation and divergence:

  • TRMT2B shows varying degrees of conservation across species, particularly in the catalytic domain

  • Some species (notably members of the Bovinae subfamily) contain a tyrosine substitution in place of the catalytic cysteine, rendering the enzyme catalytically inactive

  • Antibody epitope selection must account for species-specific sequence variations

• Species-specific antibody validation:

  • Current commercially available antibodies show reactivity with human and rat TRMT2B

  • Cross-reactivity testing with recombinant TRMT2B from the species of interest

  • Western blot validation using tissue from relevant species

• Biological function differences:

  • In bovine species, mitochondrial tRNAs lack m5U54 modification due to catalytically inactive TRMT2B

  • Species-specific compensatory mechanisms may exist

  • Correlation between TRMT2B activity and RNA modification patterns across species

• Experimental design adaptations:

  • Species-specific primers for RT-qPCR analysis

  • Optimization of antibody dilutions for each species

  • Appropriate positive and negative control tissues

• Comparative analysis considerations:

  • Alignment of TRMT2B sequences across species to identify conserved regions

  • Selection of antibodies targeting highly conserved epitopes for cross-species studies

  • Functional assessment of enzyme activity in different species

These considerations are crucial for proper experimental design and interpretation when studying TRMT2B across different model organisms and in comparative studies.

What approaches can be used to study the functional significance of TRMT2B-mediated RNA modifications?

Several sophisticated experimental approaches can elucidate the functional significance of TRMT2B-mediated m5U modifications:

• Genetic manipulation approaches:

  • CRISPR/Cas9-mediated TRMT2B knockout (complete elimination)

  • siRNA-mediated TRMT2B knockdown (partial reduction)

  • Expression of catalytically inactive TRMT2B mutants (dominant-negative approach)

  • Rescue experiments with wild-type vs. mutant TRMT2B

• Molecular and biochemical analyses:

  • Quantification of m5U levels in RNA by LC-MS/MS

  • Analysis of RNA stability using ethidium bromide-induced RNA decay assays

  • Assessment of tRNA charging status using acidic-PAGE

  • Thermal stability assays to examine RNA structural integrity

• Translational and respiratory function assessment:

  • Analysis of mitochondrial translation using metabolic labeling

  • Measurement of respiratory chain complex activities (I, III, and IV)

  • Oxygen consumption rate and extracellular acidification rate measurements

  • Assessment of mitochondrial membrane potential

• Stress response investigations:

  • Exposure to thermal stress (43°C) to assess RNA stability under heat shock

  • Oxidative stress challenges to evaluate mitochondrial function under stress

  • Nutrient deprivation to assess metabolic adaptation

• Structural studies:

  • Cryo-EM analysis of mitoribosome assembly with and without TRMT2B

  • Investigation of structural changes in modified vs. unmodified RNAs

  • Molecular dynamics simulations to predict the impact of m5U modifications on RNA structure

These approaches provide complementary insights into the functional significance of TRMT2B and its catalyzed modifications in both normal physiology and disease states.

How can TRMT2B antibodies be integrated into multiomics approaches for comprehensive studies?

TRMT2B antibodies can be integrated into multiomics experimental designs to provide holistic understanding of mitochondrial RNA modification systems:

• Proteomics integration:

  • Immunoprecipitation of TRMT2B followed by mass spectrometry to identify protein interaction partners

  • Correlation of TRMT2B protein levels with global proteomic changes in knockout/knockdown models

  • Post-translational modification analysis of TRMT2B under different cellular conditions

• Transcriptomics approaches:

  • RNA-seq analysis following TRMT2B manipulation to identify broader transcriptional effects

  • Correlation between TRMT2B activity and changes in mitochondrial gene expression

  • Integration with epitranscriptomic mapping of m5U modifications

• Epitranscriptomics methods:

  • Antibody-based enrichment of TRMT2B-bound RNA followed by sequencing

  • Mapping of m5U modifications across the mitochondrial transcriptome

  • Correlation between modification status and RNA processing/stability

• Metabolomics correlations:

  • Analysis of metabolic changes in TRMT2B knockout/knockdown systems

  • Focus on mitochondrial metabolism and respiratory function

  • Integration with respiratory chain complex activity measurements

• Mitoribosome structural biology:

  • Cryo-EM analysis of mitoribosome assembly intermediates in TRMT2B-depleted cells

  • Structural mapping of m5U modifications and their impact on rRNA folding

  • Integration with functional ribosome studies

Example integration workflow:

• Generate TRMT2B knockout/knockdown cellular models

• Validate using TRMT2B antibodies (Western blot, immunofluorescence)

• Perform RNA-seq, proteomics, and epitranscriptomics analysis

• Measure functional consequences (respiratory chain activity, mitochondrial translation)

• Integrate datasets to build comprehensive model of TRMT2B function

This multiomics approach provides deeper insights than any single methodology alone, revealing both direct and indirect consequences of TRMT2B activity.

What are the key considerations for developing and validating novel TRMT2B antibodies?

For researchers developing new TRMT2B antibodies or validating existing ones, several critical factors should be considered:

• Epitope selection strategy:

  • Target unique regions that distinguish TRMT2B from TRMT2A and other methyltransferases

  • Avoid highly conserved methyltransferase domains that could lead to cross-reactivity

  • Consider using the N-terminal region (amino acids 1-250) which has been successfully used as an immunogen

  • Analyze species conservation if cross-species reactivity is desired

• Validation criteria for specificity:

  • Testing in TRMT2B knockout cell lines as negative controls

  • Western blot showing single band at expected molecular weight (50-56 kDa)

  • Peptide competition assays to confirm epitope specificity

  • Absence of signal in irrelevant cellular compartments

• Application-specific validation:

  • For WB: Confirmation of expected band size and absence in knockout samples

  • For IHC: Appropriate subcellular localization (mitochondrial) and absence in knockout tissues

  • For IF: Colocalization with mitochondrial markers like TOM20

  • For IP: Ability to pull down TRMT2B confirmed by mass spectrometry

• Performance characteristics documentation:

  • Sensitivity (minimum detectable amount of TRMT2B)

  • Dynamic range of detection

  • Reproducibility across multiple experiments

  • Lot-to-lot consistency if producing multiple batches

• Standardized validation dataset:

  • Panel of positive control tissues/cells with known TRMT2B expression

  • Negative controls (knockout/knockdown samples)

  • Dilution series to determine optimal working concentration

  • Comparison with existing validated antibodies if available